{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:07:48Z","timestamp":1787962068251,"version":"build-2784847793"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Regulatory T cells (Tregs) play a central role in maintaining immune homeostasis. Therefore, owing to their unique immunomodulatory function, their adoptive transfer has been investigated as a novel therapeutic modality. Recent progress in cell manufacturing has allowed the application of Tregs as cell therapy products, and several are being tested in human clinical trials. Furthermore, several clinical trials are aimed at evaluating Treg modulation methods, including cytokine administration, monoclonal antibodies, Treg depletion, and adoptive Treg transfer. Among these, adoptive Treg transfer is a promising cell and gene therapy modality that is potentially beneficial for both genetic and non-genetic diseases, including autoimmunity. To determine the current trends in research on Treg-based therapies, we performed a database search and found that investigational clinical trials have been performed not only for autoimmunity but also for a wide range of diseases. In this mini review, we introduce early benchmarking Treg trials together with recent advances in research on Treg biology shown in non-genetic diseases and not just limited to autoimmunity.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1762753","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:19:53Z","timestamp":1774588793000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Regulatory T cells in the era of cell and gene therapy: biology, clinical translation, and future prospects"],"prefix":"10.3389","volume":"17","author":[{"given":"Yohei","family":"Sato","sequence":"first","affiliation":[{"name":"Core Research Facilities, Research Center for Medical Sciences, The Jikei University School of Medicine","place":["Tokyo, Japan"]},{"name":"Laboratory of Immune Cell Therapy, Project Research Units, Research Center for Medical Sciences, The Jikei University School of Medicine","place":["Tokyo, Japan"]},{"name":"Immunology and Allergy Research Unit, Department of Otorhinolaryngology, Head & Neck Surgery, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nri3650","article-title":"FOXP3 and scurfy: how it all began","volume":"14","author":"Ramsdell","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/nyas.13011","article-title":"From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation","volume":"1417","author":"Bacchetta","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/cei.13290","article-title":"Mechanisms of human FoxP3(+) T(reg) cell development and function in health and disease","volume":"197","author":"Attias","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.014","article-title":"Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy","volume":"41","author":"Tay","year":"2023","journal-title":"Cancer Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression - implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1166135","article-title":"Opportunities for Treg cell therapy for the treatment of human disease","volume":"14","author":"Bluestone","year":"2023","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20060772","article-title":"CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells","volume":"203","author":"Liu","year":"2006","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/00008480-200112000-00007","article-title":"IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena","volume":"13","author":"Bennett","year":"2001","journal-title":"Curr Opin Pediatr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/83707","article-title":"X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy","volume":"27","author":"Wildin","year":"2001","journal-title":"Nat Genet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202149358","article-title":"Regulatory T-cell development in the tumor microenvironment","volume":"52","author":"Itahashi","year":"2022","journal-title":"Eur J Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41423-021-00742-4","article-title":"Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy","volume":"19","author":"Huppert","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-11-3687","article-title":"T-regulatory cells: key players in tumor immune escape and angiogenesis","volume":"72","author":"Facciabene","year":"2012","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-293795","article-title":"Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics","volume":"117","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clim.2014.03.016","article-title":"Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up","volume":"153","author":"Marek-Trzonkowska","year":"2014","journal-title":"Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28459","article-title":"A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation","volume":"64","author":"Todo","year":"2016","journal-title":"Hepatology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30167-7","article-title":"Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1\/2A trials","volume":"395","author":"Sawitzki","year":"2020","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0041-4","article-title":"Next-generation regulatory T cell therapy","volume":"18","author":"Ferreira","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxac084","article-title":"The potential for treg-enhancing therapies in nervous system pathologies","volume":"211","author":"Olson","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.06.003","article-title":"Regulatory T cells in allergic diseases","volume":"138","author":"Noval Rivas","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.iac.2006.02.008","article-title":"Mechanisms of allergen-specific immunotherapy: T-regulatory cells and more","volume":"26","author":"Verhagen","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"B26","unstructured":"Bacchetta\n              R\n            \n          \n          CD4^LVFOXP3 in Participants With IPEX\n          \n          2022"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202149210","article-title":"Towards gene therapy for IPEX syndrome","volume":"52","author":"Borna","year":"2022","journal-title":"Eur J Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.01.005","article-title":"Isolation of CD4+CD25+ regulatory T cells for clinical trials","volume":"12","author":"Hoffmann","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.12.8338","article-title":"Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients","volume":"177","author":"Battaglia","year":"2006","journal-title":"J Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.200.supp.176.2","article-title":"Functional reprogramming of regulatory T cells in the absence of Foxp3","volume":"20","author":"Charbonnier","year":"2019","journal-title":"Nat Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1223","article-title":"Rapamycin and abundant TCR stimulation are required for the generation of stable human induced regulatory T cells","volume":"9","author":"Kim","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2021.104378","article-title":"Rapamycin facilitates differentiation of regulatory T cells via enhancement of oxidative phosphorylation","volume":"365","author":"Chen","year":"2021","journal-title":"Cell Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167457","article-title":"Rapamycin rescues loss of function in blood-brain barrier-interacting Tregs","volume":"9","author":"Baeten","year":"2024","journal-title":"JCI Insight"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.jaci.2019.11.043","article-title":"Treatment with rapamycin can restore regulatory T-cell function in IPEX patients","volume":"145","author":"Passerini","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0000000000004866","article-title":"Low-dose interleukin-2 therapy: fine-tuning treg in solid organ transplantation","volume":"108","author":"Amini","year":"2024","journal-title":"Transplantation"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1016\/j.immuni.2024.07.016","article-title":"Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics","volume":"57","author":"Raeber","year":"2024","journal-title":"Immunity"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3246","article-title":"Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes","volume":"359","author":"Sockolosky","year":"2018","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018440","article-title":"Prevention of acute GVHD using an orthogonal IL-2\/IL-2Rbeta system to selectively expand regulatory T cells in vivo","volume":"141","author":"Ramos","year":"2023","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/sj.mt.6300341","article-title":"Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3","volume":"16","author":"Allan","year":"2008","journal-title":"Mol Ther"},{"key":"B40","doi-asserted-by":"publisher","first-page":"215ra174","DOI":"10.1126\/scitranslmed.3007320","article-title":"CD4(+) T cells from IPEX patients convert into functional and stable regulatory T cells by FOXP3 gene transfer","volume":"5","author":"Passerini","year":"2013","journal-title":"Sci Transl Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1214","article-title":"Human-engineered Treg-like cells suppress FOXP3-deficient T cells but preserve adaptive immune responses in vivo","volume":"9","author":"Sato","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"101150","DOI":"10.1016\/j.omtm.2024.101199","article-title":"A novel FOXP3 knockout-humanized mouse model for pre-clinical safety and efficacy evaluation of Treg-like cell products","volume":"31","author":"Sato","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz0571","article-title":"CRISPR-based gene editing enables FOXP3 gene repair in IPEX patient cells","volume":"6","author":"Goodwin","year":"2020","journal-title":"Sci Adv"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay6422","article-title":"Gene editing to induce FOXP3 expression in human CD4(+) T cells leads to a stable regulatory phenotype and function","volume":"12","author":"Honaker","year":"2020","journal-title":"Sci Transl Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.stem.2018.12.003","article-title":"Lentiviral gene therapy in HSCs restores lineage-specific foxp3 expression and suppresses autoimmunity in a mouse model of IPEX syndrome","volume":"24","author":"Masiuk","year":"2019","journal-title":"Cell Stem Cell"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1172\/jci82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J Clin Invest"},{"key":"B47","unstructured":"Safety & Tolerability study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients\n          \n          2021"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2017.06.009","article-title":"Antigen-specific regulatory T cells: are police CARs the answer","volume":"187","author":"Dawson","year":"2017","journal-title":"Transl Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mol Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92865","article-title":"T cells expressing chimeric antigen receptor promote immune tolerance","volume":"2","author":"Pierini","year":"2017","journal-title":"JCI Insight"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101385","article-title":"High-affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory T cells","volume":"32","author":"Cochrane","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003161","article-title":"Clinical grade Treg: GMP isolation, improvement of purity by CD127 depletion, Treg expansion, and Treg cryopreservation","volume":"3","author":"Peters","year":"2008","journal-title":"PloS One"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15700","article-title":"Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation","volume":"20","author":"Sanchez-Fueyo","year":"2020","journal-title":"Am J Transplant"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-022-00358-x","article-title":"Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation","volume":"30","author":"Proics","year":"2023","journal-title":"Gene Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102986","article-title":"Engineered Treg cells: The heir to the throne of immunotherapy","volume":"144","author":"Stucchi","year":"2024","journal-title":"J Autoimmun"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adj9331","article-title":"Human OX40L-CAR-T(regs) target activated antigen-presenting cells and control T cell alloreactivity","volume":"16","author":"Rui","year":"2024","journal-title":"Sci Transl Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1267762","article-title":"Unlocking the potential of Tregs: Innovations in CAR technology","volume":"10","author":"Requejo Cier","year":"2023","journal-title":"Front Mol Biosci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1604483","article-title":"Treg cell therapy manufacturability: Current state of the art, challenges and new opportunities","volume":"16","author":"Stoops","year":"2025","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1090721","article-title":"Barriers to Treg therapy in Europe: From production to regulation","volume":"10","author":"Hennessy","year":"2023","journal-title":"Front Med (Laus)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.01.004","article-title":"Principles of regulatory T cell function","volume":"56","author":"Dikiy","year":"2023","journal-title":"Immunity"},{"key":"B61","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/eji.201948131","article-title":"Treg cell therapy: How cell heterogeneity can make the difference","volume":"51","author":"Giganti","year":"2021","journal-title":"Eur J Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/jleuko\/qiae049","article-title":"Stability and plasticity of regulatory T cells in health and disease","volume":"116","author":"Contreras-Castillo","year":"2024","journal-title":"J Leukoc Biol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12172","article-title":"Treg functional stability and its responsiveness to the microenvironment","volume":"259","author":"Barbi","year":"2014","journal-title":"Immunol Rev"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.744763","article-title":"Polyclonal regulatory T cell manufacturing under cGMP: A decade of experience","volume":"12","author":"Balcerek","year":"2021","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1626085","article-title":"Navigating the manufacturing, testing and regulatory complexities of regulatory T cells for adoptive cell therapy","volume":"16","author":"Pikor","year":"2025","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.it.2023.04.005","article-title":"Engineered Treg cells as putative therapeutics against inflammatory diseases and beyond","volume":"44","author":"Bittner","year":"2023","journal-title":"Trends Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101604","article-title":"From rough to refined: Applying diamond standards to CAR Treg development","volume":"33","author":"Hamilton","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1186224","article-title":"Potency assays and biomarkers for cell-based advanced therapy medicinal products","volume":"14","author":"Capelli","year":"2023","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41540-024-00355-3","article-title":"Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics","volume":"10","author":"Kirouac","year":"2024","journal-title":"NPJ Syst Biol Appl"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adm8859","article-title":"Harnessing regulatory T cells to establish immune tolerance","volume":"16","author":"Ho","year":"2024","journal-title":"Sci Transl Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-0445-3_14","article-title":"Regulatory T cell-mediated tissue repair","volume":"1064","author":"Hong","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"7863","DOI":"10.1038\/s41467-024-51353-2","article-title":"Local administration of regulatory T cells promotes tissue healing","volume":"15","author":"Nayer","year":"2024","journal-title":"Nat Commun"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1502139","article-title":"Cutting edge: Regulatory T cells facilitate cutaneous wound healing","volume":"196","author":"Nosbaum","year":"2016","journal-title":"J Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxac123","article-title":"Treg specialization and functions beyond immune suppression","volume":"211","author":"Astarita","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.940705","article-title":"The dark side of Tregs during aging","volume":"13","author":"Palatella","year":"2022","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1762753\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:19:56Z","timestamp":1774588796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1762753\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":75,"alternative-id":["10.3389\/fimmu.2026.1762753"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1762753","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"article-number":"1762753"}}